Savran Technologies Inc. specializes in advanced non-invasive diagnostic technologies, particularly focusing on the capture and detection of ultra-rare cells from blood samples. Their patented micro-fluidic designs enable a streamlined workflow that can operate with or without a centrifuge, achieving high processing speeds and over 90% capture efficiency. The technology is capable of isolating both fixed and live cells while maintaining near-100% purity and single-cell capture capability. This gentle processing ensures that the cells remain healthy for downstream analysis, making it suitable for high-throughput applications in various medical fields.

The company's technology has significant applications in cancer diagnostics, particularly in the capture of circulating tumor cells (CTCs) from patients with solid tumors such as breast, lung, and pancreatic cancers. Savran Technologies has validated its CTC capture technology through a Phase 2 clinical trial involving triple-negative breast cancer patients. Additionally, their technology is being developed for prenatal diagnostics, allowing for the non-invasive isolation and genetic analysis of circulating fetal cells in maternal blood. This capability provides a comprehensive view of fetal health and access to an intact genome, showcasing the potential of Savran's technology in enhancing diagnostic accuracy and patient care.

United States

We are biotech company located in the Boston area, with a mission to revolutionize non-invasive diagnostics. The systems we are developing allow monitoring cancer patients'​ progress, as well as looking very early into pregnancy to gain a complete genetic picture of the fetus, all with a simple blood test. 


Savran Technologies Inc.

Company Details